On this week's podcast, the "Gray Sheet" team spoke about who has filled a newly established FDA position overseeing the device inspections program, the removal of a warning letter from the agency's website tied to an off-label marketing suit, what 23andMe addressed with FDA to relaunch a slimmed down direct-to-consumer genetic testing service after a two-year hiatus, bioabsorbable stents and more.
